• Start: 0.5 mg/week
• Increase by 0.5 mg per week until prolactin levels are normal
• Maximum dose: 3 mg on any 1 day (no more than 4.5 mg/week)

• 1 or 2 times per week

• Long-half-life allows for once- or twice-weekly administration
•  It is recommended that cabergoline be taken with meals
• Very common side effects (may affect more than 1 in 10 people): Valvulopathy (including regurgitation) and related disorders (pericarditis and pericardial effusion), headache, dizziness/vertigo, nausea, dyspepsia, gastritis, abdominal pain, asthenia and fatigue.
• Common side effects (may affect up to 1 in 10 people): Somnolence, depression, postural hypotension, hot flushes, constipation, vomiting, breast pain, asymptomatic decreases in blood pressure (≥20 mmHg systolic and ≥10 mmHg diastolic).

Cabergoline is licensed for the treatment of dysfunctions associated with hyperprolactinaemia, including amenorrhoea, oligomenorrhoea, anovulation and galactorrhoea. Cabergoline is indicated in patients with prolactin-secreting pituitary adenomas (micro- and macroprolactinomas), idiopathic hyperprolactinaemia, or empty sella syndrome with associated hyperprolactinaemia, which represent the basic underlying pathologies contributing to the above clinical manifestations.
Please see product SmPC for full detai

• Irrespective of the final dose, the optimum response with the minimum side effects is best achieved by gradual introduction for the treatment of hyperprolactinaemia
•For Adults:
   ⇒ Initially: 1-1.25 mg/day at bedtime, increasing after 2-3 days to 2-2.5mg
at bed time
    ⇒ Then increase by 1mg at 2-3 day intervals, until a dose of 2.5mg twice daily is achieved
   ⇒ Dose may then be increased by 2.5mg daily at 2-3 day intervals until prolactin levels are normal
   ⇒ Maximum dose: 30 mg/day
Most patients with hyperprolactinaemia have responded to 7.5mg daily, in divided doses, but doses of up to 30mg daily have been used

• First drug used to treat hyperprolactinemia; introduced >30 years ago
• Short half-life requires frequent dosing​​​​​
• Should always be taken with food
• Prescribing in children and adolescents (aged 7-17) should be limited to Paediatric Endocrinologists.
• Common side effects (affect less than 1 in 10 people): Headache, Drowsiness, Feeling and being sick, Constipation, Blocked nose.

Bromocriptine is licensed for the treatment of hyperprolactinaemia in men and women with hypogonadism and/or galactorrhoea. 
Please see product SmPC for full details

• Start: 25 µg/day for 3 days
• Increase to 50 µg/day for 3 days
• Maintain a dose of 75 µg/day from day 7 onwards
• Dose may be increased by stepwise 75-150 µg/day, as necessary
• Maximum dose: Doses of ≥300 μ/day are required in less than 1/3 of patients

• 1 time per day

• Since dopaminergic stimulation may lead to symptoms of orthostatic hypotension, the dose should be initiated gradually, and given only at bedtime.
• Very common side effects (affect more than 1 in 10 patients treated): Nausea, Vomiting, Headache, Dizziness, Tiredness
• Common side effects (affect between 1 in 10 and 1 in 100 patients treated): Anorexia, Abdominal pain, Constipation or diarrhoea, Insomnia, Oedema, Flushing, Nasal congestion and a drop in blood pressure which may result in fainting.
​​​​
Quinagolide is licensed for the treatment of hyperprolactinaemia (idiopathic or originating from a prolactin-secreting pituitary microadenoma or macroadenoma).
Please see product SmPC for full details